{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:30:27Z","timestamp":1778200227929,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.tjog.2020.09.008","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T12:17:24Z","timestamp":1605615444000},"page":"828-834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231"],"prefix":"10.1016","volume":"59","author":[{"given":"Tinghua","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changbin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2020.09.008_bib1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Canc"},{"key":"10.1016\/j.tjog.2020.09.008_bib2","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.tjog.2020.09.008_bib3","article-title":"Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: a meta-analysis","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.tjog.2020.09.008_bib4","first-page":"1299","article-title":"Peiminine serves as an adriamycin chemosensitizer in gastric cancer by modulating the EGFR\/FAK pathway","volume":"39","author":"Tang","year":"2018","journal-title":"Oncol Rep"},{"key":"10.1016\/j.tjog.2020.09.008_bib5","first-page":"57","article-title":"The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine","volume":"23","author":"Javan-Noughabi","year":"2018","journal-title":"J\u00a0Res Med Sci"},{"key":"10.1016\/j.tjog.2020.09.008_bib6","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1158\/1535-7163.MCT-08-0021","article-title":"Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin","volume":"7","author":"Kovalchuk","year":"2008","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.tjog.2020.09.008_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0962-8924(99)01519-6","article-title":"PTEN: a tumour suppressor that functions as a phospholipid phosphatase","volume":"9","author":"Maehama","year":"1999","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.tjog.2020.09.008_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10549-018-4779-x","article-title":"Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer","volume":"170","author":"Petrossian","year":"2018","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.tjog.2020.09.008_bib9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000354757","article-title":"Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase\/akt\/mammalian target of rapamycin signaling pathway","volume":"8","author":"Hasson","year":"2013","journal-title":"Breast Care"},{"key":"10.1016\/j.tjog.2020.09.008_bib10","doi-asserted-by":"crossref","first-page":"15591","DOI":"10.18632\/oncotarget.24570","article-title":"Treatment of oral cancer using magnetized paclitaxel","volume":"9","author":"Nakakaji","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.tjog.2020.09.008_bib11","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/ijc.24837","article-title":"Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis","volume":"126","author":"Shafer","year":"2010","journal-title":"Int J Canc"},{"key":"10.1016\/j.tjog.2020.09.008_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzym Regul"},{"key":"10.1016\/j.tjog.2020.09.008_bib13","first-page":"335","article-title":"Classification, treatment strategy, and associated drug resistance in breast cancer","volume":"16","author":"Tang","year":"2016","journal-title":"Clin Breast Canc"},{"key":"10.1016\/j.tjog.2020.09.008_bib14","first-page":"1487","article-title":"Autophagy activation promotes bevacizumab resistance in glioblastoma by suppressing Akt\/mTOR signaling pathway","volume":"15","author":"Huang","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.tjog.2020.09.008_bib15","first-page":"4611","article-title":"Optimal control problems arising in cell-cycle-specific cancer chemotherapy","volume":"35","author":"Swierniak","year":"2017","journal-title":"Cell Prolif"},{"key":"10.1016\/j.tjog.2020.09.008_bib16","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/ni.3868","article-title":"Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor","volume":"18","author":"Maj","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.tjog.2020.09.008_bib17","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdm170","article-title":"Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling","volume":"18","author":"Beeram","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.tjog.2020.09.008_bib18","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1158\/1078-0432.CCR-04-0035","article-title":"Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant akt activity","volume":"10","author":"de Graffenried","year":"2004","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.tjog.2020.09.008_bib19","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","article-title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","volume":"16","author":"Hurvitz","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2020.09.008_bib20","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/0008-5472.CAN-06-4261","article-title":"AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin\/p70S6K1 pathway","volume":"67","author":"Liu","year":"2007","journal-title":"Canc Res"},{"key":"10.1016\/j.tjog.2020.09.008_bib21","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1074\/jbc.M706287200","article-title":"Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells","volume":"283","author":"Eckstein","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.tjog.2020.09.008_bib22","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ctrv.2013.03.009","article-title":"Targeting the PI3K\/AKT\/mTOR and Raf\/MEK\/ERK pathways in the treatment of breast cancer","volume":"39","author":"Saini","year":"2013","journal-title":"Canc Treat Rev"},{"key":"10.1016\/j.tjog.2020.09.008_bib23","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s10637-014-0149-7","article-title":"Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors","volume":"32","author":"Ewald","year":"2014","journal-title":"Invest N Drugs"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455920302199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455920302199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T18:19:23Z","timestamp":1760897963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455920302199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1028455920302199"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2020.09.008","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2020.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}